Načítá se...
Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia
BACKGROUND: Hypopigmentation is an infrequently reported adverse effect of imatinib mesylate (IM) in chronic myeloid leukemia (CML), but there are no reports from Arab or Saudi patients. Thus, we assessed the frequency and impact of hypopigmentation in patients with chronic myeloid leukemia (CML) ta...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2009-04-01
|
| Edice: | Hematology/Oncology and Stem Cell Therapy |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S165838760950026X |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|